LAURA GERENCER

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family HOLLAND, MI NPI 1013429323

General Payments — all program years on this page

$714.40

  • Category: General Payments
  • Program years: PY2021–2024
  • Record count: 29
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $355.43 across 19 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $355.4319

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Novo Nordisk AS $170.2315
Acerta Pharma LLC $124.741
PFIZER INC. $24.411
Esperion Therapeutics, Inc. $21.931
Lilly USA, LLC $14.121

By program year

Program yearAmountRecords
2021 $124.991
2022 $168.416
2023 $65.573
2024 $355.4319

Records — PY2024 (19)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1100244413 Novo Nordisk Inc $20.03 09/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100264548 Novo Nordisk Inc $7.29 06/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100269240 Novo Nordisk Inc $9.33 08/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100269752 Novo Nordisk Inc $11.67 07/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100367107 Novo Nordisk Inc $11.48 05/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100381293 Novo Nordisk Inc $12.42 02/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100393722 Novo Nordisk Inc $13.85 04/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100427328 Novo Nordisk Inc $8.02 03/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100440225 Novo Nordisk Inc $14.78 01/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100454684 Novo Nordisk Inc $12.24 05/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100513049 Novo Nordisk Inc $8.85 06/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100608836 Novo Nordisk Inc $7.92 01/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100624778 Novo Nordisk Inc $13.38 02/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100649781 Novo Nordisk Inc $8.99 02/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100651881 Novo Nordisk Inc $9.98 10/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105230812 AstraZeneca Pharmaceuticals LP $124.74 12/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1129467076 Esperion Therapeutics, Inc. $21.93 01/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131628959 PFIZER INC. $24.41 02/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135783392 Lilly USA, LLC $14.12 01/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.